Urinary Tract: Non-Catheter Associated Urinary Tract
Infection/Cystitis

Infection/Cystitis						
CLASSIFICATION	CLINICAL FINDINGS	RECOMMENDED EMPIRIC REGIMENS	CLINICAL CONSIDERATIONS			
Asymptomatic Bacteriuria	 Pyuria (urinalysis > 5-10 WBC) OR Positive urine culture (≥ 100,000 cfu/mL)† AND No sign or symptoms (see below) 	No antibiotics unless the patient is: Scheduled for urologic procedure Pregnant Scheduled Urologic Procedure: SMX/TMP 1 DS tablet PO Q12H OR Ciprofloxacin 500 mg PO OR Ciprofloxacin 400 mg IV Q12H Initiate within 24 hours prior to procedure and until foley removed Pregnant: Amoxicillin 500 mg PO Q8H for 3 to 7 days OR Cephalexin 500 mg PO Q6H for 3 to 7 days OR Nitrofurantoin (MacroBID)‡ 100 mg PO Q12H for 5 days	 Obtaining routine cultures in asymptomatic patients is <u>NOT</u> recommended Antibiotics do <u>NOT</u> decrease asymptomatic bacteriuria or prevent subsequent UTI 			
Symptomatic: Complicated ≥ 1 of the following: • Male • Pyelonephritis • Antibiotic use in previous 90 days • History of infection with MDRO • Immunocompromised • Functional or anatomic urologic abnormality • Severe sepsis	 Pyuria (Urinalysis ≥ 5 WBC) AND Positive urine culture (≥ 100,000 cfu/mL)† AND Presence of symptoms: - Dysuria - Urgency - Frequency - Suprapubic pain AND/OR Presence of signs: - Fever (≥ 100.4°F) - Altered mental status - Leukocytosis 	Outpatient: SMX/TMP 1 DS tablet PO Q12H OR Nitrofurantoin (MacroBID)* 100 mg PO Q12H OR Ciprofloxacin 250 - 500 mg PO Q12H Inpatient: Cefazolin 2 gm IV Q8H OR Cefepime 1 gm IV Q12H OR Ceftriaxone 1 gm IV Q24H OR Ampicillin/sulbactam 1.5 gm IV Q6H Known or suspected ESBL bacteria: Meropenem 1 gm IV Q24H OR Ertapenem 1 gm IV Q24H OR Duration of Treatment: 7 to 14 days	 Narrow antibiotic therapy when organism and susceptibilities are known Follow-up urine cultures or urinalysis are only warranted for ongoing symptoms. They should <i>NOT</i> be obtained routinely to monitor response to therapy 			

cfu= colony forming units; ESBL= extended spectrum beta-lactamase; H= hour(s); IV= intravenous; MDRO= multi-drug resistant organism; PO= by mouth; Q= every; SMX/TMP= sulfamethoxazole/trimethoprim; UTI= Urinary Tract Infection; WBC= white blood cell count

†Positive urine culture:

For Women: 2 consecutive voided urine specimens with isolation of >10⁵ cfu/mL of the same bacterial strain For Men: A single, clean-catch, voided urine specimen with isolation of >10⁵ cfu/mL from 1 bacterial species ‡Nitrofurantoin: Contraindicated if CrCl< 60 mL/min <u>AND</u> only indicated in acute cystitis

NOTE: Dosing based on normal renal function. Refer to Table of Contents for section on Antimicrobial Dosing for Adult Patients Based on Renal Function

Urinary Tract: Non-Catheter Associated Urinary Tract
Infection/Cystitis

CLASSIFICATION	CLINICAL FINDINGS	RECOMMENDED EMPIRIC REGIMENS	CLINICAL CONSIDERATIONS
Symptomatic Uncomplicated/ Cystitis • Female AND • No criteria for complicated (see previous page)	 Pyuria (Urinalysis: ≥ 5 WBC) AND Positive urine culture (≥ 100,000 cfu/mL)† AND Presence of symptoms: Dysuria Urgency Frequency Suprapubic pain 	Nitrofurantoin (MacroBID)* 100 mg PO Q12H for 5 days OR SMX/TMP 1 DS tablet PO Q12H for 3 days Alternative agents should be avoided if possible due to the risk of C. difficile AND antibiotic resistance. IF patient has an allergy/contraindication to the above antibiotics alternatives include: Ciprofloxacin 250 mg PO Q12H for 3 days OR Cephalexin 500 mg PO Q12H for 3 days	Urine culture should be performed ONLY IF: History of multiple UTIS OR MDRO infection(s) Narrow antibiotic therapy when organism and susceptibilities are known Follow-up urine cultures or UA are only warranted for on-going symptoms. They should NOT be obtained routinely to monitor response to therapy

Urinary Tract: Prostatitis

CLASSIFICATION	Preferred Regimen	Alternative Regimens	CLINICAL CONSIDERATIONS
Outpatient	Ciprofloxacin 500 mg PO Q12H	SMX/TMP 1 DS tablet PO Q12H OR Levofloxacin 500 mg PO once daily (Requires ID Consult)	Beta-lactams DO NOT have adequate penetration into prostate
		Duration of Treatment: 28 days	

cfu= colony forming units; DS= double strength; H= hour(s); MDRO= multi-drug resistant organism; PO= by mouth; Q= every; SMX/TMP= sulfamethoxazole/trimethoprim; UA= urinalysis; UTI= Urinary Tract Infection; WBC= white blood cell count

†Positive urine culture:

For Women: 2 consecutive voided urine specimens with isolation of $>10^5$ cfu/mL of the same bacterial strain For Men: A single, clean-catch, voided urine specimen with isolation of $>10^5$ cfu/mL from 1 bacterial species

‡Nitrofurantoin: Contraindicated if CrCl< 60 mL/min AND only indicated in acute cystitis

NOTE: Dosing based on normal renal function. Refer to Table of Contents for section on Antimicrobial Dosing for Adult Patients Based on Renal Function

References

- 1. Hooton TM, Bradley SF, Cardena DD, et al. Diagnosis, prevention, and treatment of catheter-associated urinary tract infection in adults: 2009 international clinical practice guidelines from the Infectious Disease Society of America. CID 2010;50:625-63.
- 2. Nicolle LE, et al. Infectious Diseases Society of America guidelines for the diagnosis and treatment of asymptomatic bacteriuria in adults. Clin Infect Dis. 2005 Mar 1;40(5):643-54.
- 3. Gupta K, et al. International clinical practice guidelines for the treatment of acute uncomplicated cystitis and pyelonephritis in women: A 2010 update by the Infectious Diseases Society of America and European Society for Microbiology and Infectious Diseases. Clin Infect Dis. 2011 Mar 1;52(5):e103-20.